Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Genflow Biosciences Plc is a biotechnology company based in the United Kingdom, specializing in the development of gene therapies aimed at addressing the biological mechanisms of aging. Founded in 2020 and with additional research facilities in Belgium, the company leverages advanced genetic engineering techniques to target the SIRT6 gene variant, a gene associated with longevity as observed in centenarians. Genflow’s primary focus is on innovating therapeutics that deliver this gene variant via adeno-associated virus (AAV) vectors, with the intention to extend healthspan and delay the onset of age-related diseases in humans and dogs. Its lead product, GF-1002, represents a gene therapy candidate designed for intravenous administration to potentially treat conditions such as metabolic dysfunction-associated steatohepatitis (MASH). The company also develops veterinary gene therapies, highlighting its cross-species research orientation. Through its research and development activities, Genflow Biosciences Plc contributes to the evolving landscape of longevity science and regenerative medicine, aiming to address the healthcare and societal challenges posed by an aging global population.
£0.02
+£0.00 (+2.50%)
EOD Jul 3, 2026
Negative free cash flow of -£1M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£0.00
Net Income (TTM)
-£1M
▲ +10.7% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (TTM)
-£1M
▼ -32.7% YoY
Op. Cash Flow (TTM)
-£1M
▼ -32.7% YoY
Net Debt
-£112K
Net Cash Position
Cash & Equiv.
£112K
Continue Research
Genflow Biosciences (GENF.XLON)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Genflow Biosciences scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Genflow Biosciences scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 3 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh GENF.XLON's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.